MedTrace Logo

First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

NCT02335814 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2018-02-09

No results posted yet for this study

Summary

This first-in-human (FIH) clinical trial is a Phase 1/1b, open-label, sequential-group, dose-escalation and cohort expansion study evaluating the safety, PK, PD, and antitumor activity of FLX925 in subjects with relapsed or refractory AML.

Conditions

Interventions

DRUG

FLX925

Sponsors & Collaborators

  • RAPT Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jorge E Cortes, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-08
Primary Completion
2017-05-03
Completion
2017-05-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02335814 on ClinicalTrials.gov